SCHEMBL9907481

SCHEMBL9907481

Cc1cnc2ccc(C(=O)O)cc2c1-c1cccc(F)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 3/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CREBBP Q92793 1/20 0.37
SLC22A12 Q96S37 1/20 0.37
IP6K1 Q92551 1/20 0.37
IP6K3 Q96PC2 1/20 0.37
IP6K2 Q9UHH9 1/20 0.37
PTGFR P43088 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
MAPK14 Q16539 1/20 0.36
RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907386 0.88 SLC22A12 (0.41) HTR5AALDH1A1POLBHPGDL3MBTL1
SCHEMBL9907451 0.88 HTR5A (0.49) HTR5ALMNASMN1; SMN2CSNK2A2CSNK2B
SCHEMBL9907480 0.88 NR1H2 (0.43) HTR5ASMN1; SMN2ALDH1A1HPGDCREBBP
SCHEMBL9907401 0.86 HTR5A (0.46) HTR5AALDH1A1POLBCSNK2A2CSNK2B
SCHEMBL9907843 0.85 HTR5A (0.59) HTR5A
SCHEMBL9907448 0.83 HTR5A (0.47) HTR5ALMNASMN1; SMN2ALDH1A1PTGFR
SCHEMBL9907449 0.81 HTR5A (0.50) HTR5A
SCHEMBL9907400 0.80 HTR5A (0.54) HTR5A
SCHEMBL9907470 0.79 CSNK2A2 (0.41) ALDH1A1POLBHPGDL3MBTL1CSNK2A2
SCHEMBL9907494 0.79 HTR5A (0.55) HTR5ALMNASMN1; SMN2CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885LMNA 4287/4885SMN1; SMN2 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.